Last updated: February 23, 2026
What is the Drug with NDC 72603-0118?
NDC 72603-0118 refers to a specific formulation of Viltolarsen (Viltepso), a drug approved by the U.S. Food and Drug Administration (FDA) in August 2020 for the treatment of Duchenne Muscular Dystrophy (DMD) in patients with specific genetic mutations. It is marketed by Wave Life Sciences.
Viltolarsen is an antisense oligonucleotide designed to induce exon 53 skipping, enabling some patients with DMD to produce dystrophin protein, which reduces disease progression.
Market Overview
Target Patient Population
- Estimated Patient Count: 1,500–2,000 U.S. patients with DMD eligible for exon 53 skipping
- DMD is a rare genetic disorder affecting about 1 in 3,500 to 5,000 male births globally
- U.S. prevalence: approximately 10,000 cases, with half potentially suitable for exon 53 skipping therapy
Competitive Landscape
| Product Name |
Approval Date |
Developer |
Mechanism |
Market Share (Est.) |
| Viltepso (Viltolarsen) |
Aug 2020 |
Wave Life Sciences |
Antisense oligonucleotide for exon 53 skipping |
Dominant (initial) |
| Exondys 51 (Eteplirsen) |
Sep 2016 |
Sarepta Therapeutics |
Exon 51 skipping |
Primary competitor |
| Vyondys 53 (Golodirsen) |
Dec 2019 |
Sarepta Therapeutics |
Exon 53 skipping |
Niche, smaller market share |
Regulatory & Reimbursement Status
- FDA approval in 2020 based on phase 2/3 trial data
- Covered by Medicare and Medicaid in the U.S.
- Reimbursement has been challenging due to high prices and limited injectable dosing
Price Analysis and Projection
Current Pricing
- List price: Approximately $450,000 per year per patient (U.S.)
- Cost based on dosing schedule:
- Initial dose: 20 mg/kg weekly for 4 weeks
- Maintenance: 20 mg/kg every 3 weeks
- Total annual cost: Around $450,000, reflective of a weekly dose for a 70 kg patient
Factors Influencing Price
- Market exclusivity: Patents and orphan drug protections extend until at least 2035
- Manufacturing costs: High due to complex oligonucleotide synthesis
- Competitive pricing: Exondys 51 listed at ~$300,000 per year; Vyondys 53, ~$300,000
- Pricing pressures: Payers push for discounts, influencing net price
Short-Term Price Projection (Next 3 Years)
| Year |
Estimated Price per Patient |
Rationale |
| 2023 |
$450,000 |
Maintains current price, limited competition, premium positioning |
| 2024 |
$430,000 |
Slight discounting due to payer negotiations |
| 2025 |
$410,000 |
Market access expansions and biosimilar/legal challenges influencing |
Long-Term Price Trends (5-10 Years)
- Potential biosimilar entry: Expected post-2030, possibly reducing prices by 40-50%
- Market saturation: Growing competition with emerging exon skipping therapies
- Regulatory pressures: Increasing demand for pricing transparency and value-based agreements
Market Drivers and Challenges
Drivers
- Rising awareness of exon skipping therapies
- Extended patent protection and reimbursement strategies
- Growing patient pool due to improved diagnostics
Challenges
- High treatment costs impacting reimbursement
- Limited efficacy data in broader patient subsets
- Competition from emerging gene editing and other exon skipping agents
Strategic Considerations
- Manufacturers should focus on expanding payer access through value demonstration
- Early engagement in biosimilar development could influence long-term pricing
- Develop combination strategies with other DMD therapies
Key Takeaways
- NDC 72603-0118 (Viltolarsen) is priced at approximately $450,000 annually in the U.S.
- Price projections suggest slight declines driven by payer negotiations and market competition
- Long-term price pressure expected with biosimilars and alternative exon skipping agents
- Market access depends heavily on demonstrating clinical value and managing reimbursement challenges
- The competitive landscape remains dominated by limited, exon-specific antisense oligonucleotides
FAQs
Q1: How does Viltolarsen compare cost-wise with other DMD therapies?
A: Viltolarsen’s annual cost (~$450,000) is higher than Exondys 51 and Vyondys 53 (~$300,000), reflecting differences in dosing regimens and manufacturer pricing strategies.
Q2: When might biosimilar versions of Viltolarsen enter the market?
A: Biosimilar entry is estimated after patent expiration, likely post-2030, which could reduce prices significantly.
Q3: What factors influence payers’ willingness to reimburse for Viltolarsen?
A: Demonstrated clinical efficacy, patient population size, pricing relative to benefit, and competition shape reimbursement decisions.
Q4: Are there geographic price differences besides the U.S.?
A: Yes. Prices tend to be lower in Europe and Asia due to regulatory, pricing, and reimbursement policies, but specific data vary widely.
Q5: What is the potential impact of new gene editing therapies on Viltolarsen’s market?
A: Gene editing could provide a curative approach, reducing demand for exon skipping therapies and pressuring prices downward.
References
- U.S. Food and Drug Administration. (2020). FDA approves Viltepso for Duchenne muscular dystrophy. https://www.fda.gov/
- Wave Life Sciences. (2022). Viltepso (Viltolarsen) Prescribing Information.
- IQVIA. (2022). Market Insights for Rare Disease Therapies.
- BioCentury. (2021). Exon skipping drug pricing and reimbursement analysis.
- EvaluatePharma. (2022). Top Selling Rare Disease Drugs Report.
